Thus, a combination of TFAM with si-Smad or MAPK inhibitors had greater inhibitory effects on the TGF-β1-induced epithelial–mesenchymal transition in IEC-6 cells, which suggests that TFAM might represent a novel therapeutic strategy for the treatment of intestinal fibrosis in Crohn’s disease. Here, TFAM is linked to Crohn disease.